Oxaliplatin
- PDF / 170,156 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 19 Downloads / 165 Views
1 S
Oxaliplatin Neuropathy: case report
A 59-year-old woman developed neuropathy during treatment with oxaliplatin for metastatic pancreatic ductal adenocarcinoma [dosage and route not stated]. The woman, who had a history of triple negative subtype breast cancer (treated with surgery, radiotherapy and adjuvant chemotherapy), presented with poor quality of life because of uncontrolled back pain in 2016. After further investigations, she was diagnosed with metastatic pancreatic ductal adenocarcinoma. She received 13 cycles of FOLFIRINOX regimen consisting of folinic acid, fluorouracil, irinotecan and oxaliplatin from 8 November 2016 to 31 May 2017. Following treatment with FOLFIRINOX regimen, a very good partial response in the pancreatic and liver lesions was observed along with the resolution of back pain. However, she developed oxaliplatin-induced neuropathy [time to reaction onset and outcome not stated]. The woman’s chemotherapy was discontinued due to increasing neuropathy. She was followed up every 3 months for CA19-9 measurements and imaging. Sixteen months after the chemo-holiday (in October 2018), an increase in her CA19-9 levels was observed, despite the disease stability. Due to limiting neuropathy, oxaliplatin could not be restarted. Hence, she was restarted on only FOLFIRI consisting of folinic acid, fluorouracil and irinotecan. After eight cycles, disease progression was observed along with increase in CA19-9 levels. Thereafter, a BRCA mutational test was performed, which revealed BRCA1 germline mutation. On 11 June 2019, she started receiving olaparib. After three cycles of olaparib, shrinkage of both pancreatic and liver lesions was observed, along with decrease in CA19-9 levels. She continued to receive olaparib with ongoing response and no side effects. Pimenta JR, et al. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review. Case Reports in Oncology 13: 904-910, No. 2, May-Aug 2020. Available from: URL: http:// doi.org/10.1159/000508533
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803519488
Reactions 5 Dec 2020 No. 1833
Data Loading...
